Grifols acquires Novartis’ diagnostics unit, which includes in vitro diagnostic technology and a couple of U.S. offices, in a deal worth $1.7 million.

Novartis (NYSE:NVS) unloaded its diagnostics units today, selling the division to Grifols (NSDQ:GRFS) in a deal worth $1.7 million, the companies announced today.

Barcelona-based Grifols said that the deal includes Novartis’ nucleic acid amplification techniques in addition to other in vitro diagnostic products & technology for transfusion medicine & immunology. Grifols is also nabbing a U.S. manufacturing plant and commercial offices in U.S., Switzerland & Hong Kong.